Can you buy ipamorelin on its own?
Ipamorelin is the one molecule here that reaches the pituitary a different way — recorded as a ghrelin mimetic, where the other four are GHRH analogs. So when you go to buy it, what is actually on sale?
Where to buy either
CoreAge Rx
$99 per month
- What it is
- dose not stated
- What it buys
- Sermorelin
- Read
- September 2026
See CoreAge Rx pricingWe may be paid if you sign up through this link.
ElitePhysiqMD
$267.30 per month
- What it is
- dose not stated
- What it buys
- Sermorelin
- Read
- September 2026
Longevixx
$249 per month
- What it is
- dose not stated
- What it buys
- Sermorelin
- Read
- September 2026
Oak Longevity
Publishes no figure for these on its own page. The record says what was looked at and when.
What the listings say
3 of the 14 sellers whose pages here list ipamorelin at all. Between them they account for 5 of the 19 priced listings on this site that name it. None of those 19 listings buys ipamorelin by itself. Every figure that names it is a pairing or a package, and the molecule arrives with something else attached.
The sellers listing it: ElitePhysiqMD, Longevixx, Youth & Soul. Each figure below is on that seller’s own record, with the page it was read from and the day it was read.
Listings that buy ipamorelin on its own
0 of 19
5 of the other 19 name ipamorelin inside a pairing or a package; the remaining 14 do not name it at all. A figure that buys a pairing is not a price for either molecule in it, so none of them is printed here as an ipamorelin cost.
Listings that name ipamorelin at all
5 of 19
Named by 3 of 14 sellers. Being named is not the same as being priced, and this page is the distance between the two.
Of the listings that name it, how many state a dose
0 of 5
200–300 µg, 2 or 3 injections a day, often with CJC-1295 (no DAC) is what the literature records as the reported use (Dominikowski et al. 2026). None of the listings here says how much of it the money buys, so there is nothing to check that against.
Counted from the 14 seller records behind the board, every figure read off the seller’s own page and dated. The per-seller working is on the seller records.
What those figures actually buy
Here is every listing in these records that names ipamorelin, with what else is in it. They are in record order and not sorted by size, because sorting them would imply they are comparable and they are not: each one buys a different bundle of things, 2 different kinds of price are represented, and 5 of 5 state no dose at all.
- ElitePhysiqMD — $274.50 per month, listed as “Tesamorelin / Ipamorelin”. It also buys Tesamorelin.
- ElitePhysiqMD — $315.00 per month, listed as “CJC-1295 + Ipamorelin”. It also buys CJC-1295, with or without DAC not stated.
- Longevixx — $329 per month, listed as “CJC-1295 / Ipamorelin”. It also buys CJC-1295, with or without DAC not stated.
- Longevixx — $349 per month, listed as “Tesamorelin / Ipamorelin”. It also buys Tesamorelin.
- Youth & Soul — $149 per month, listed as “Growth Hormone Optimization”. It also buys Sermorelin; NAD+ sublingual tablets (250mg); Methylene Blue; IGF-1 & hormone panel blood work review; physician monitoring & dose optimization.
Not the same measurement
These 5 figures use 1 billing cycle and 2 kinds of price between them, and 5 of 5 state no dose. They are not one measurement and no arithmetic makes them one, so this site names no cheapest here or anywhere.
Two of them will not say what the other half is
2 of the 5 pairings put ipamorelin beside a CJC-1295 product, and neither of them does say which CJC-1295. That is not a pedantic distinction. The two molecules sold under that name are as far apart as anything on this site: the DAC form measured 5.8–8.1 days in a trial in healthy adults, and the form without DAC is not reported in humans. Weekly or daily, in other words, and the listing does not say which. Which CJC-1295 are you buying? follows that one all the way down.
So on 2 of these listings the buyer is being offered two molecules, cannot buy the one they came for on its own, and is not told which version of the other one is in the box. Which CJC-1295 are you buying? is the page about that half, and what has and has not been measured about how long the pairing takes to work is the page about the whole.
The same unresolved listings appear as their own chip on the board’s molecule filter, as their own panel on the CJC-1295 page, and as their own bar in the census of what the roster does not state on the home page. One state, carried the same way everywhere it is rendered.
So the comparison is not the one the page in front of you is making
A reader who has arrived at sermorelin vs ipamorelin is comparing two molecules, and that comparison is real: they reach the pituitary through different receptors and clear at very different speeds. But it is not the comparison on offer at the checkout. 12 of the 19 listings here buy sermorelin on its own; 0 buy ipamorelin on its own.
The choice actually available in these records is between sermorelin and a package containing ipamorelin, and those two things do not differ only in their active molecule. One of the 5 pairings bundles blood work and physician monitoring; two bundle a second peptide whose form is unstated. A comparison that treats them as two versions of one purchase is comparing the wrong pair.
What the records show
- 0 of 19 listings buy ipamorelin on its own.
- 5 name it inside something else, across 3 of 14 sellers.
- 5 of 5 state no dose, so none of them can be checked against the 200–300 µg, 2 or 3 injections a day, often with CJC-1295 (no DAC) the literature reports.
What this does not tell you
19 listings is not the market. The 14 sellers here were chosen to cover the shapes a price can take, not to survey an industry, and a company that does sell ipamorelin on its own may simply not be among them. What is published here is a statement about 19 listings that were read, on the dates recorded beside them — not about every seller in the United States.
The matrix carries no safety row for any molecule. Each of the 5 records carries a mechanism, a half-life, a selectivity note, a regulatory status and a reported use, and nothing about adverse events. That is a gap in what has been done here, not a statement that there is nothing to report, and it is not filled in from memory.
And the pharmacology this page leans on is only as good as its citations, which are counted rather than claimed:
What this site will not print
No figure on this page is offered as the cost of ipamorelin, because no listing here is one. The figures above are printed as what they are — the price of a package that contains it — and never divided into a per-molecule number the seller never quoted.
Sources
Every pharmacological figure on this page comes from one of the documents below. Seller figures are read off the seller’s own page and carry the date they were read.
The complete reference list for all 5 molecules is on the sources page.
8 documents, in the order the figures above use them. The date on each is the one printed on the document.
- Venkova K, Mann W, Nelson R, Greenwood-Van Meerveld B. Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus.Document date: 2009-06. PMID 19289567, doi:10.1124/jpet.108.149211. Read September 2026.
- Gobburu JV, Agersø H, Jusko WJ, Ynddal L. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers.Document date: 1999-09. PMID 10496658, doi:10.1023/a:1018955126402. Read September 2026.
- Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue.Document date: 1998-11. PMID 9849822, doi:10.1530/eje.0.1390552. Read September 2026.
- Dominikowski A, Rękoś Z, Olejarz M, Szczepanek-Parulska E, Domin R, Ruchała M. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.Document date: 2026-06-18. PMID 42395176, PMC13322892, doi:10.3389/fendo.2026.1822475. Read September 2026.
- Esposito P, Barbero L, Caccia P, Caliceti P, D'Antonio M, Piquet G, Veronese FM. PEGylation of growth hormone-releasing hormone (GRF) analogues.Document date: 2003-09-26. PMID 14499707, doi:10.1016/s0169-409x(03)00109-1. Read September 2026.
- Food and Drug Administration, Department of Health and Human Services. Determination That GEREF (Sermorelin Acetate) Injection, 0.5 Milligrams Base/Vial and 1.0 Milligrams Base/Vial, and GEREF (Sermorelin Acetate) Injection, 0.05 Milligrams Base/Amp, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness.Document date: published 2013-03-04, signed 2013-02-26. 78 FR 14095, FR Doc. 2013-04827, Docket No. FDA-2012-P-1071. Read September 2026.
- Theratechnologies Inc., prescribing information approved by the Food and Drug Administration. EGRIFTA SV (tesamorelin) for injection, for subcutaneous use — full prescribing information.Document date: label face date: Revised 03/2024; label version published 2026-07-31. SPL set id 3d783378-b02d-4f19-99dd-0fc91a042224, Initial U.S. Approval 2010. Read September 2026.
- Theratechnologies Inc., prescribing information approved by the Food and Drug Administration. EGRIFTA WR (tesamorelin) for injection, for subcutaneous use — full prescribing information.Document date: label face date: Revised 03/2025; label version published 2026-08-03. SPL set id 839334d3-8c1d-4c26-9036-2ab524a6ea75, Initial U.S. Approval 2010. Read September 2026.